RT Journal Article
SR Electronic
T1 Autoantibodies linked to autoimmune diseases associate with COVID-19 outcomes
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.02.17.22271057
DO 10.1101/2022.02.17.22271057
A1 Baiocchi, Gabriela Crispim
A1 Vojdani, Aristo
A1 Rosenberg, Avi Z
A1 Vojdani, Elroy
A1 Halpert, Gilad
A1 Ostrinski, Yuri
A1 Zyskind, Israel
A1 Filgueiras, Igor Salerno
A1 Schimke, Lena F.
A1 Marques, Alexandre H. C.
A1 Giil, Lasse M.
A1 Lavi, Yael Bublil
A1 Silverberg, Jonathan I.
A1 Zimmerman, Jason
A1 Hill, Dana Ashley
A1 Thornton, Amanda
A1 Kim, Myungjin
A1 De Vito, Roberta
A1 Fonseca, Dennyson Leandro M.
A1 Plaça, Desireé Rodrigues
A1 Freire, Paula Paccielli
A1 Camara, Niels Olsen Saraiva
A1 Calich, Vera Lúcia Garcia
A1 Heidecke, Harald
A1 Lattin, Miriam T.
A1 Ochs, Hans D.
A1 Riemekasten, Gabriela
A1 Amital, Howard
A1 Cabral-Marques, Otavio
A1 Shoenfeld, Yehuda
YR 2022
UL http://medrxiv.org/content/early/2022/02/18/2022.02.17.22271057.abstract
AB The SARS-CoV-2 infection is associated with increased levels of autoantibodies targeting immunological proteins such as cytokines and chemokines. Reports further indicate that COVID-19 patients may develop a wide spectrum of autoimmune diseases due to reasons not fully understood. Even so, the landscape of autoantibodies induced by SARS-CoV-2 infection remains uncharted territory. To gain more insight, we carried out a comprehensive assessment of autoantibodies known to be linked to diverse autoimmune diseases observed in COVID-19 patients, in a cohort of 248 individuals, of which171 were COVID-19 patients (74 with mild, 65 moderate, and 32 with severe disease) and 77were healthy controls. Dysregulated autoantibody serum levels, characterized mainly by elevated concentrations, occurred mostly in patients with moderate or severe COVID-19 infection, and was accompanied by a progressive disruption of physiologic IgG and IgA autoantibody signatures. A similar perturbation was found in patients with anosmia. Notably, autoantibody levels often accompanied anti-SARS-CoV-2 antibody concentrations, being both indicated by random forest classification as strong predictors of COVID-19 outcome, together with age. Moreover, higher levels of autoantibodies (mainly IgGs) were seen in the elderly with severe disease compared with young COVID-19 patients with severe disease. These findings suggest that the SARS-CoV-2 infection induces a broader loss of self-tolerance than previously thought, providing new ideas for therapeutic interventions.Competing Interest StatementThe authors have declared no competing interest.Funding StatementWe acknowledge the patients for participation in this study. We would like to acknowledge the contributions of Lev Rochel Bikur Cholim of Lakewood (led by Rabbi Yehuda Kasirer and Mrs. Leeba Prager) and their hundreds of volunteers who participated in collecting samples for this research through the MITZVA Cohort. We thank Immunosciences and Cyrex Laboratories for financial support and INOVA Diagnostics for providing their diagnostic ELISA kits for autoimmunity at a very discounted rate. Furthermore, we would like to thank Vilma Samayoa, David Cisneros, Roberto Melgar, Dana Ashley Hill and Amanda Thornton for technical assistance. We also thank the Sao Paulo Research Foundation (FAPESP grants: 2020/07972-1 to GCB; 2020/09146-1 to PPF; 2020/11710-2 to DRP, 2018/18886-9, 2020/01688-0, and 2020/07069-0 to OCM), and the Coordination for the Improvement of Higher Education Personnel (CAPES) Financial Code 001 (grant to ISF) for financial support.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:APPROVED BY INTEGREVIEW IRB NOVEMBER 21, 2020I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data present in this manuscript are provided as Supplementary files. All R packages used in this manuscript are available at the following link. https://github.com/gabrielacbaiocchi/Autoantibodies-linked-to-autoimmune-diseases-associate-with-COVID-19-outcomes.git